Point72 Asset Management L.P. purchased a new position in Magenta Therapeutics Inc (NASDAQ:MGTA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 8,100 shares of the company’s stock, valued at approximately $109,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tiverton Asset Management LLC bought a new position in shares of Magenta Therapeutics in the 2nd quarter worth $125,000. Dean Capital Investments Management LLC bought a new position in shares of Magenta Therapeutics in the 2nd quarter worth $558,000. Citadel Advisors LLC bought a new position in shares of Magenta Therapeutics in the 2nd quarter worth $1,172,000. BlackRock Inc. bought a new position in shares of Magenta Therapeutics in the 2nd quarter worth $1,350,000. Finally, Voya Investment Management LLC bought a new position in shares of Magenta Therapeutics in the 2nd quarter worth $3,387,000. 30.31% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently commented on the company. JPMorgan Chase & Co. assumed coverage on Magenta Therapeutics in a research report on Monday, July 16th. They issued an “overweight” rating and a $18.00 price target for the company. Cowen assumed coverage on Magenta Therapeutics in a research report on Monday, July 16th. They issued an “outperform” rating for the company. Wedbush assumed coverage on Magenta Therapeutics in a research report on Monday, July 16th. They issued an “outperform” rating and a $22.00 price target for the company. Goldman Sachs Group assumed coverage on Magenta Therapeutics in a research report on Monday, July 16th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Zacks Investment Research lowered Magenta Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 18th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $19.33.

Shares of NASDAQ:MGTA opened at $11.67 on Wednesday. Magenta Therapeutics Inc has a 1 year low of $11.25 and a 1 year high of $16.33.

Magenta Therapeutics (NASDAQ:MGTA) last announced its earnings results on Thursday, August 9th. The company reported ($3.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($2.03). equities research analysts anticipate that Magenta Therapeutics Inc will post -2.8 earnings per share for the current year.

Magenta Therapeutics Company Profile

Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.

Read More: Market Capitalization – What it Means for Investors

Institutional Ownership by Quarter for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.